Navigation Links
Jubilant and BioLeap Announce New Partnership in Drug Discovery
Date:1/13/2009

NOIDA, India and NEW HOPE, Pa., Jan. 13 /PRNewswire/ -- Jubilant Organosys Ltd., headquartered at Noida, near New Delhi, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a drug discovery partnership with BioLeap, LLC, USA. Under this partnership, BioLeap and Jubilant will integrate BioLeap's leading edge computational fragment based drug design platform with Jubilant's expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform. The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimization to IND (Investigational New Drug) candidate selection for multiple therapeutic areas.

Commenting on the development, Sri Mosur, CEO & President, Jubilant Biosys, said: "We are very pleased to partner with BioLeap to offer the pharmaceutical industry our combined 'best in class' preclinical drug discovery capabilities."

Gerald Evans, BioLeap Chief Business Officer added, "We are delighted to have the opportunity to offer our partners the combined capabilities of Jubilant and BioLeap. This partnership leverages and combines the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development with BioLeap's leading edge computational fragment-based design capabilities, to deliver high quality, cost-effective pre-clinical drug discovery services."

BioLeap's platform technology is completely "in-silico," and it quickly predicts binding information providing drug designers new insights to efficiently create novel molecules and/or improve existing molecules without the limitations of library screening, thereby reducing the time and cost of traditional screening methods.

Many current screening programs have hit barriers with regards to finding small molecule candidates for viable validated targets because of limitations in chemical diversity. BioLeap's technology provides a viable solution to this current paradigm. The combined strengths of JBL/BioLeap partnership would be most attractive to companies engaged in rational drug design in therapeutic areas where Structural Biology plays a key role, which includes but is not limited to any of the top twenty pharmaceutical companies working on anti-infectives, oncology, CNS and other therapeutic areas.

About Jubilant Biosys

Jubilant Biosys Ltd. (http://www.jubilantbiosys.com) is a subsidiary of Jubilant Organosys Ltd., which provides integrated drug discovery and development solutions to the global pharmaceutical industry. The 120,000 sq. ft. state of the art Jubilant Biosys Center in Bangalore integrates the capabilities of over 300 scientists specializing in multiple disciplines including biology, chemistry, structural biology, pharmacology, molecular modeling, crystallography and information technology to support collaborations with global pharma companies in USA, Europe and Japan.

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and Health Care. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.

About BioLeap

BioLeap is a leader in computational fragment-based drug design. The company's proprietary design technology and process successfully addresses one of the biggest problems in pre-clinical drug discovery: the limitation of druggable and patentable leads for important biological targets. BioLeap is using its capabilities to advance its internal programs and has also entered into numerous drug design collaborations with pharmaceutical partners.

Further information about Jubilant Organosys is available at http://www.jubl.com and about BioLeap at http://www.bioleap.com.


'/>"/>
SOURCE Jubilant Organosys Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Eurofins announces the appointment of Sean ... Eurofins Scientific Inc. (ESI). Mr. Murray will bring ... and entrepreneurial experience in leading international business teams. As the National ... market to uphold Eurofins, status as the global leader in bio-analytical ... , , ...
(Date:12/8/2016)... Dec. 8, 2016  Anaconda BioMed S.L., a pre-clinical ... the next generation neuro-thrombectomy system for the treatment of ... G. Jovin, MD to join its Scientific Advisory Board ... strategic network of scientific and clinical experts to Anaconda ... the ANCD BRAIN ® to its clinical phase. ...
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/5/2016)... Dec. 5, 2016  The Office of Justice ... "Can CT Scans Enhance or Replace Medico Legal ... of supporting or replacing forensic autopsies with postmortem ... In response to recommendations made by ... using CT scans as a potential component of ...
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
Breaking Biology News(10 mins):